



PATENT ABSTRACTS OF JAPAN

(11) Publication number: **2003277262 A**(43) Date of publication of application: **02.10.2003**(51) Int. Cl. **A61K 31/4439**

A61K 9/08, A61K 47/14, A61P 1/04

(21) Application number: **2002075138**(71) Applicant: **TAKADA KANJI**(22) Date of filing: **18.03.2002**(72) Inventor: **TAKADA KANJI****(54) TECHNIQUE OF IMPROVING
BIOAVAILABILITY OF LANSOPRASOLE****(57) Abstract:**

PROBLEM TO BE SOLVED: To provide a novel oral preparation technique of enhancing the solubility and absorbability of lansoprasole in the digestive tract to

reliably attain a therapeutically effective drug concentration in blood.

SOLUTION: The preparation is prepared by formulating lansoprasole with a mixture of a 6-18C fatty acid/glycerol ester with a 6-18C fatty acid/macrogol ester.

COPYRIGHT: (C)2004,JPO

DELPHION

RESEARCH

PRODUCTS

INSIDE DELPHION

Log Out | Work Files | Saved Searches

My Account


Search: Quick/Number Boolean Advanced Derwent

Help


The Delphion Integrated ViewGet Now: ☒ PDF | [File History](#) | [Other choices](#)


Tools: Add to Work File: Create new Work File

Add

View: [INPADOC](#) | Jump to: TopGo to: [Derwent](#) [Email this to a friend](#)

 Title: **JP2003277262A2: TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE**


 Derwent Title: Lansoprazole formulation for use as anticancer agent, contains lansoprazole and ester mixture of glycerol- and macrogol-ester of fatty acid, and has increased bioavailability in digestive tract after oral administration
[[Derwent Record](#)]


 Country: JP Japan


 Kind: A2 Document Laid open to Public inspection


 Inventor: TAKADA KANJI;


 Assignee: TAKADA KANJI
[News, Profiles, Stocks and More about this company](#)

 Published / Filed: 2003-10-02 / 2002-03-18

 Application Number: JP2002000075138


 IPC Code: Advanced: [A61K 9/08](#); [A61K 31/4439](#); [A61K 47/14](#); [A61P 1/04](#);
Core: [A61K 31/4427](#); [A61P 1/00](#); more...
IPC-7: [A61K 9/08](#); [A61K 31/4439](#); [A61K 47/14](#); [A61P 1/04](#);

 Priority Number: 2002-03-18 JP2002000075138


 Abstract: PROBLEM TO BE SOLVED: To provide a novel oral preparation technique of enhancing the solubility and absorbability of lansoprasole in the digestive tract to reliably attain a therapeutically effective drug concentration in blood.

SOLUTION: The preparation is prepared by formulating lansoprasole with a mixture of a 6-18C fatty acid/glycerol ester with a 6-18C fatty acid/macrogol ester.

COPYRIGHT: (C)2004,JPO

 Family: None

 Other Abstract Info: [DERABS C2003-884852](#)



[Nominate this for the Gallery...](#)



Copyright © 1997-2006 The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)

DELPHION

RESEARCH

PRODUCTS

INSIDE DELPHION

Log Out Work Files Saved Searches

My Account

Search: Quick/Number Boolean Advanced Derwent

Help

Derwent Record

✉ Email this to a friend

View: Expand Details Go to: Delphion Integrated View

Tools: Add to Work File: Create new Work File

- Derwent Title: **Lansoprazole formulation for use as anticancer agent, contains lansoprazole and ester mixture of glycerol- and macrogol-ester of fatty acid, and has increased bioavailability in digestive tract after oral administration**
- Original Title: ☒ **JP2003277262A2: TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE**
- Assignee: **TAKADA K Individual**
- Inventor: **None**
- Accession/Update: **2003-884852 / 200382**
- IPC Code: **A61K 31/4439 ; A61K 9/08 ; A61K 47/14 ; A61P 1/04 ;**
- Derwent Classes: **B02;**
- Manual Codes: **B04-C03(Polymers [general]) , B06-D05(Heterocyclic fused ring with 2 rings (5+6 membered) and two N) , B10-G02(Carboxylic esters) , B14-H01 (Anticancer general and other)**
- Derwent Abstract: (**JP2003277262A2**) **Novelty** - Dissolution-absorption of lansoprazole in the digestive tract after oral administration is increased by adding ester mixture of glycerol ester of 6-18C fatty acid and macrogol ester of 6-18C fatty acid with respect to lansoprazole.
ACTIVITY - Cytostatic.
 No test details are given.
MECHANISM OF ACTION - None given.
Use - As anticancer agent.
Advantage - By adding the ester mixture, lansoprazole is absorbed reliably from the formulation and bioavailability of lansoprazole is increased sharply. Laparotomy was performed in Wistar male rat with body weight of 350 plus or minus 25 g under pentobarbital anesthesia. Suspension containing 5 mg of lansoprazole in 1 ml of 0.5% carboxymethylcellulose was poured into duodenum of rat at a dose of 5 mg/kg. Blood samples were collected from jugular vein after 30 minutes and 1-6 hours, and concentration of lansoprazole in plasma was measured by high performance liquid chromatography. Lansoprazole concentration (micro g/ml) in plasma was 0.15 plus or minus 0.03 (after 30 minutes), 0.21 plus or minus 0.05 (after 1 hour), 0.26 plus or minus 0.03 (after 2 hours), 0.22 plus or minus 0.06 (after 3 hours), 0.16 plus or minus 0.05 (after 4 hours), 0.11 plus or minus 0.04 (after 5 hours) and 0.05 plus or minus 0.02 (after 6 hours). The gentamycin concentration in plasma after administering control formulation to rat was 0.05 plus or minus 0.01 (after 2 hours). All other plasma samples showed concentration, which was less than detection limit (0.02 micro g/ml) after 30 minutes, 1 hour and 3-6 hours.

Dwg.0/0

Family: PDF Patent Pub. Date Derwent Update Pages Language IPC Code

☒ **JP2003277262A2** * 2003-10-02 200382 3 English A61K 31/4439

Local appls.:

Priority Number:

Application Number	Filed	Original Title

JP2002000075138	2002-03-18	TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE
-----------------	------------	--

[? Chemical Indexing Codes:](#) [Show chemical indexing codes](#)

[? Specific Compound Numbers:](#) [Show specific compounds](#)

[? Related Accessions:](#)

Accession Number	Type	Derwent Update	Derwent Title
C2003-252140	C		
1 item found			

[? Title Terms:](#) FORMULATION ANTICANCER AGENT CONTAIN ESTER MIXTURE GLYCEROL ESTER FATTY ACID INCREASE DIGEST TRACT AFTER ORAL ADMINISTER

[Pricing](#) [Current charges](#)

Derwent Searches:	Boolean Accession/Number Advanced
--------------------------	---

Data copyright Thomson Derwent 2003



Copyright © 1997-2006 The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)